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This study was to evaluate the eﬀects of thalidomide on expression of adhesion molecules in liver cirrhosis. The cirrhosis was in-
ducedinWistarratsbyintraperitonealinjectionofCCl4,andthalidomide(10mg/kg/dayor100mg/kg/day)wasgiven byintragas-
tric administration for 8 weeks. Liver histopathology and immunohistochemistry were signiﬁcantly improved and the expressions
of ICAM-1, VCAM-1, E-selectin, and TNF-α mRNA and protein were decreased signiﬁcantly in rats treated with a high dose of
thalidomide. Close positive correlation was observed in the expression of the TNF-α m R N Aa n dt h a to fI C A M - 1 ,V C A M - 1 ,a n dE -
selectin mRNA, respectively. These results indicate that thalidomide exerts its eﬀect on the downregulation of adhesion molecules
via TNF-α signaling pathway to inhibit liver ﬁbrosis.
Copyright © 2006 Peng Lv et al. This is an open access article distributed under the Creative Commons Attribution License, which
permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
INTRODUCTION
Adhesion molecules are proteins expressed on a variety of
cells, which mediate the interaction between endothelial cells
with lymphocytes, monocytes, and leukocytes [1].
Intercellular adhesion molecule-1 (ICAM-1) and vas-
cular cellular adhesion molecule-1 (VCAM-1), two mem-
bers of the immunoglobulin supergene family, play key
roles in promoting migration of immunological cells from
the circulation to target site in the inﬂammatory state
[2, 3]. Gir´ on-Gonz´ alez et al reported that endothelial ac-
tivation plays an active role in modiﬁcations of the cir-
culatory status of cirrhotic patients, then de novo expres-
sion of ICAM-1 and VCAM-1 on endothelial cells medi-
ates the transmigration of inﬂammatory cells, which in-
duce inﬂammation and tissue damage in liver [4]. Up-
regulated ICAM-1 or VCAM-1 expression in chronic liver
disease has been reported in several studies, suggesting that
they may play roles in the pathogenesis of chronic hep-
atitis or cirrhosis [5–12]. The selectin family of cell ad-
hesion molecules is generally thought to promote inﬂam-
matory reactions by facilitating leukocyte recruitment [13].
High levels of soluble E-selectin have been reported in
acute and chronic inﬂammatory disorders. Cervello et al re-
ported that high serum levels of soluble E-selectin are asso-
ciated with chronic hepatitis and liver cirrhosis, especially in
the liver cirrhosis patients soluble E-selectin decreased with
disease severity according to the Child-Pugh classiﬁcation
[14].
Thalidomide was withdrawn from the world market in
the early 1960s for its well-known tragic teratogenic eﬀects.
Butinrecentyears,manyclinicaltrialshavevalidateditsclin-
ical utility in treatment of various hematologic malignancies
such as multiple myeloma and solid tumors, and a variety of
inﬂammatory and autoimmune diseases on the basis of its
important eﬀects on inﬂammation, regulation of immuno-
logical reaction and angiogenesis [15, 16]. Thalidomide tar-
gets leukocytes, endothelial cells, and keratinocytes, aﬀect-
ing them in diﬀerent manners and at diﬀerent cellular lev-
els.Changesinthedensityofadhesionmoleculesalterleuko-
cyte extravasation and the inﬂammatory response in the tis-
sue involved [17]. Settles et al reported that thalidomide
can signiﬁcantly reduce cell adhesion molecule expression
such as ICAM-1 and LFA-1 in human T leukemic (CEM)
cells and human umbilical vein endothelial cells (HUVEC)
and cell adhesion between them [18]. Whether the down-
regulation of adhesion molecules by thalidomide can be
used in the treatment of liver ﬁbrosis has not been reported
yet.
The aim of this study is to investigate the changes of ex-
pression of adhesion molecules such as ICAM-1, VCAM-1,
and E-selectin in the carbon tetrachloride induced cirrhosis
treated with thalidomide, and to analyze its mechanism.2 Mediators of Inﬂammation
MATERIALS AND METHODS
Animals
Sixty male Wistar rats, four to ﬁve weeks old, weighing
85–95g (obtained from Center of Experimental Animal of
Hubei Academy of Medical Sciences) were used. The rats
were housed in a temperature and humidity-controlled en-
vironment, and they were fed rat chow and water ad libitum
throughout the study period.
Experimentaldesign
The work was performed in accordance with the princi-
ples of the 1983 Declaration of Helsinki and with the ap-
proval of the ethics committee of Wuhan University. The
rats were randomly divided into four groups (each group,
n = 15) as follows: normal control group, model group,
group treated with low dose of thalidomide, group treated
with high dose of thalidomide. The rats in model group and
therapeutic groups were intraperitoneally injected with car-
bon tetrachloride (CCl4) (16.67% in peanut oil) three times
a week for 8 weeks to induce liver cirrhosis, and the rats in
normal control group only received peanut oil by intraperi-
toneal injection. Thalidomide was dissolved in normal saline
to prepare diﬀerent concentration (.1% and 1%). Thalido-
mide (10mg/kg/day or 100mg/kg/day) was given by intra-
gastric administration in the two therapeutic groups, respec-
tively, for 8 weeks, meanwhile the rats in the normal con-
trol group and model group were given the vehicle (normal
saline) for 8 weeks. All the rats were sacriﬁced at the end of
the eighth week. 5ml vein blood was obtained from the right
ventricle of heart while the rat was under ether anaesthesia,
and was stored in −80◦C. Liver tissue from the right lobe
was ﬁxed by 40g/L formaldehyde, embedded by paraﬃna n d
continual sections were taken, rest of the liver was preserved
at −80◦C.
Pathologicalexamination
Two pathologists did the pathological examination indepen-
dently after staining the sections of the liver with hematoxy-
lin-eosin(HE)stainingmethodandMassontrichromestain-
ing method.
The Knodell hepatitis activity index (HAI) was used to
grade the severity of the inﬂammation activity and ﬁbrosis
in liver. It was composed of four independent scores as fol-
lows: periportal necrosis with or without bridging necrosis
(0–10), intralobular degeneration and focal necrosis (0–4),
portal inﬂammation (0–4), and ﬁbrosis (0–4).
Serumassay
The serum was obtained by centrifugation of rat blood at
1500rmp/min for 15 minutes. Then alanine aminotrans-
ferase (ALT), aspartate aminotransferase (AST), prealbumin
(PA), albumin (ALB), and globulin (GLB) were detected by
biochemical analysis. Hyaluronic acid (HA), laminin (LN),
procollagen Type III, (PCIII), and collagen Type IV (C IV)
were detected by radioimmunoassay.
Immunohistochemistrystainingof
ICAM-1,VCAM-1,andE-selectin
The expression of markers was detected using the three-step
streptavidin-biotinimmunoperoxidasemethod.Brieﬂy,after
tissue sections were deparaﬃnized and rehydrated, they were
heated in microwave oven for 10 minutes to enhance antigen
retrieval. Slides were then incubated for 10 minutes with 3%
H2O2 to inactivate endogenous peroxidase activity. Follow-
ing a 20-minute blocking step with 5% normal goat serum
diluted in phosphate-buﬀered saline (.01% PBS), the pri-
mary antibodies (ICAM-1, Santa Cruz, Calif, USA; VCAM-
1 and E-selectin, Bosider, Wuhan, China) were applied and
incubated for 2 hours in a moisture chamber at 37◦C. Af-
ter treating with biotinylated hircine anti-mouse (or rabbit)
IgG and avidin for 30 minutes each at 37◦C, diaminobenzi-
dine1mg/mlinPBScontaining.03%hydrogenperoxidewas
appliedasthechromogen.Sectionswerecounterstainedwith
hematoxylinfor15seconds.Foreachantibody,negativecon-
trolstudieswereperformedinwhichPBSwasusedinsteadof
primary antibody.
The cytoplasm or membrane of the positive cell was
s t a i n e db r o w na n dy e l l o w .T h es e c t i o n sw e r eo b s e r v e du n d e r
the Olympus microscope by two pathologists independently.
No less than 5 high power ﬁelds (400 multiples) and no less
than1000cellswerecounted.Thenthepercentageofpositive
cells was recorded.
Westernblotanalysis
Frozen tissue was homogenized in 1ml of ice-cold ly-
sis buﬀer (10mM Tris-Hcl. PH 7.5, 10mM Nacl, .1mM
EDTA, .5% Triton-X, .02% NaN3, .2mM phenylmethyl-
sulfonyl ﬂuoride). After incubation for 30 minutes on ice,
the homogenate was centrifuged at 16000g for 30 minutes
at 4◦C, the supernatant transferred to a new tube. Pro-
tein concentration was determined using Bradford method
with BSA as standard. Total proteins (30μg) were elec-
trophoresed through standard 12% SDS-PAGE in Tris-
glycine electrophoresis buﬀer [25mm Tris, 192mM glycine
(pH 8.3), and .1% SDS] and blotted onto nitrocellulose
membrane in transferring buﬀer [380mM glycine, 50mM
Tris (pH 8.3) and 20% methanol] at 80mA for 2 hours
in a water-cooled transfer apparatus. The membrane was
pre-incubated in blocking buﬀer (TBS containing 5% non-
fat dried milk) for 2 hours at room temperature and then
probed with a primary antibody (1 : 200 diluted in the
blocking buﬀer) for overnight at 4◦C. The membrane was
washed three times with .1% Tween-PBS, then it was incu-
bated with goat anti-(rabbit IgG or mouse IgG) Ig conju-
gated with horseradish peroxidase (Santa Cruz, Calif, USA)
diluted to 1 : 2000 in the blocking buﬀer for 2 hours at room
temperature. Antibody-antigen complexes were detected by
chemiluminescence using enhanced chemiluminescent sub-
strate kit (Santa Cruz, Calif, USA). β-actin (1 : 1000 diluted
in the blocking buﬀer) was used as the housekeeping inter-
nal control. Primary antibodies used were: anti-rat TNF-α
polyclonal antibody (Santa Cruz, Calif, USA), anti-mousePeng Lv et al 3
β-actin monoclonal antibody (Sigma, Mo, USA). Images
were captured, and the signals were quantiﬁed in arbitrary
units (OD) x band area using Vilber Lourmat image analysis
system (Vilber Lourmat, Marne-la-Vallee Cedex 1, France).
The results are expressed by density ratios to β-actin.
Reversetranscriptase-polymerasechainreaction
Total RNA was extracted from the frozen liver tissue with
Trizol reagent (Invitrogen Corporation, Calif, USA), which
is based on the guanidine thiocyanate method. Frozen liver
was mechanically homogenized on ice in 1ml of ice-cold
Trizol reagent. Total RNA was dissolved in RNase-free H2O,
and quantiﬁed in duplicate by measuring the optical den-
sity (OD) at 260nm. Purity of RNA was assured by exam-
ining the OD260/OD280 ratio. Two micrograms of RNA were
reverse transcribed with oligo DT and avian myeloblastosis
virus-reverse transcriptase (RT) (Promega, Wis, USA) in a
totalvolumeof20μl.OnemicroliterofcomplementaryDNA
(cDNA) was then ampliﬁed by PCR using 1 microliter of
forward and reverse primers (50PM), 2.5mM deoxyribonu-
cleotidetriphosphates(dNTPs),2.5μl1×PCRbuﬀerand2.5
units Taq DNA polymerase (Takara, Shiga, Japan) in a ﬁnal
volume of 25μl. PCR was performed using a programmed
Thermocycler (Biometra, Goettingen Germany). The steps
of ampliﬁcation were TNF-α (95◦Cf o r3m i n ,9 4 ◦Cf o r3 0s ,
53◦Cfor30s,72◦Cfor45s,72◦C7minfor35cycles);ICAM-
1( 9 5 ◦Cf o r3m i n ,9 4 ◦C for 60s, 55◦C for 60s, 72◦Cf o r6 0s ,
72◦C7minfor32cycles);VCAM-1(95◦Cfor3min,95 ◦Cfor
60s, 55◦C for 60s, 72◦C for 60s, 72◦C7m i nf o r3 2c y c l e s ) ;
E-selectin (95◦Cf o r3m i n ,9 4 ◦C for 30s, 53◦C for 45s, 72◦C
for 60s, 72◦C7m i nf o r3 2c y c l e s ) ;G A P D H( 9 5 ◦Cf o r3m i n ,
94◦C for 30s, 53◦C for 30s, 72◦C for 45s, 72◦C7m i nf o r3 5
cycles). The primer pairs were designed from sequences pub-
lished in GenBank. The primer pairs were: TNF-α:f o r w a r d :
5 -GCCAATGGCATGGATCTCAAAG-3 ;r e v e r s e :5  -CAG-
AGCAATGACTCCAAAGT-3 ; ICAM-1: forward: 5 -CTG-
CAGAGCACAAACAGCAGAG-3 ;r e v e r s e :5  -AAGGCCG-
CAGAGCAAAAGAAGC-3 ; VCAM-1: forward: 5 -TAAGT-
TACACAGCAGTCAAATGGA-3 ;r e v e r s e :5  -CACATACA-
TAAATGCCGGAATCTT-3 ; E-selectin: forward: 5 -CAAC-
GTGCACGTTTGACTGT-3 ;r e v e r s e :5  -AGGTCAAGGCT-
TGAACACTG-3 ;GAPDH:forward:5 -TCCCTCAAGATT-
GTCAGCAA-3 ;r e v e r s e :5  -AGATCCACAACGGATACAT-
T-3 .Glyceraldehyde-3-phosphatedehydrogenase(GAPDH)
was used as internal controls, while all RT-PCR signals were
normalized to the signal of the corresponding RT product
of GAPDH to eliminate the measurement error from uneven
sample loading, and provide a semiquantitative measure of
the relative changes in gene expression. The cDNAs from all
liver samples were ampliﬁed simultaneously using aliquots
from the same PCR mixture. After the PCR ampliﬁcation,
5μl of each reaction was electrophoresed on 1.5% agarose
gels, and stained with ethidium bromide. Images were cap-
tured, and the signals were quantiﬁed in arbitrary units as
OD x band area using Vilber Lourmat image analysis system
(Vilber Lourmat, Marne-la-Vallee Cedex 1, France). The re-
sults are expressed by density ratios to GAPDH.
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Figure 1: Observation of the appearance of rat liver. Severity of the
cirrhosis of rats in the model (a) control group was much worse
than that in (b) the group treated with high dose of thalidomide.
Statisticalanalysis
Data were presented as mean ± SEM, and were analyzed
using one-way ANOVA followed by Student-Newman-Keuls
post hoc test and correlation analysis. The .05 level of proba-
bility was used as statistical signiﬁcance.
RESULTS
Healthystatusoftheratandappearanceofitsliver
In the model group, ﬁve rats died during the 8 weeks, and
the survivals appeared anorexic, loss of body weight and
tantrum, meanwhile their coat lost the gloss. The liver of
the survival rat was dark red after it was sacriﬁced. There
were many granular-nodules distributed in the surface of the
rat. The liver felt much tough and its edge became obtuse
(Figure 1(a)). Three rats died during this period in the group
treated with low dose of thalidomide (10mg/kg/day), and
generallythehealthyconditionandappearanceofliverofthe
survival rats were the same as those in the normal control
group. Only one rat died after the eight weeks in the group
treated with high dose of thalidomide (100mg/kg/day). The
healthy condition of the survival rats in this group was bet-
ter which was noted by good appetite, body weight and gloss
of coat. And there were only few granular-nodules detected
in the red surface of liver, which become smooth compared
with that of cirrhosis rat. The liver felt soft and its edge was
not obtuse (Figure 1(b)).4 Mediators of Inﬂammation
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Figure 2: Liver histopathology of the rat detected by HE staining. N represented the normal control group; M represented the model group;
L represented the group treated with low dose of thalidomide; H represented the group treated with high dose of thalidomide (original
magniﬁcation N, M, L, H, ×100).
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Figure 3:LiverhistopathologyoftheratdetectedbyMassontrichromestaining.Nrepresentedthenormalcontrolgroup;Mrepresentedthe
model group; L represented the group treated with low dose of thalidomide; H represented the group treated with high dose of thalidomide.
Fibrotic bands of liver shown in M, L, and H (original magniﬁcation N, M, L, H, ×100).
Histopathology
Figures 2 and 3 show the histopathology of the rats by HE
staining and Masson staining method. The architecture of
hepatic lobules of the normal control rats was complete,
and there was no ﬁbroplasia and inﬂammatory cell inﬁltra-
tion. But in the rats of model group, the lobules of liver
were separated and surrounded by the collagen ﬁbers, which
resulted in apparent pseudolobules. And there were severe
necrosis and fatty degeneration of hepatocytes that were
widespread in the pseudolobules of cirrhosis, meanwhile in-
ﬂammatorycellsinﬁltratedextensivelyinthestroma.Theto-
tal Knodell score was signiﬁcantly higher in the model group
than that in the normal control group (P<. 01) (Figure 4).
Compared with the model group, the ﬁbroplasia of the rat
liver in the group treated with low dose of thalidomide wasPeng Lv et al 5
Table 1: Analysis of serum liver function indexes. Data are presented as mean ± standard error of the mean. N represented the normal
control group; M represented the model group; L represented the group treated with low dose of thalidomide; H represented the group
treated with high dose of thalidomide.
Groups n ALT(U/L) AST(U/L) PA(mg/dL) ALB(g/L) GLB(g/L)
N 15 48.41 ± 7.06 118.11 ±10.76 1.03 ±0.23 42.65 ±2.34 30.34 ±1.33
M 10 160.49 ±8.14a 485.89 ±9.36a 0.44 ±0.10a 33.21 ± 2.16a 31.24 ±1.02
L 12 136.73 ±6.39ab 216.82 ±7.80ab 0.53 ±0.09a 34.58 ± 0.72a 30.43 ±1.20
H 14 62.48 ±7.08abc 141.49 ±9.53abc 1.31 ±0.14abc 40.59 ±1.39abc 30.88 ±1.29
aP<. 01 versus normal control group; bP<. 01 versus model group;
cP<. 01 group treated with high dose of thalidomide versus group treated with low dose of thalidomide.
Table 2: Analysis of serum liver ﬁbrosis indexes. Data are presented as mean ± standard errorof the mean. N represented the normal control
group; M represented the model group; L represented the group treated with low dose of thalidomide; H represented the group treated with
high dose of thalidomide.
Groups n HA(ng/mL) LN(ng/mL) PCIII(ng/mL) C IV(ng/mL)
N 15 109.13 ±15.92 31.89 ±1.63 7.23 ±1.37 26.93 ±3.17
M 10 384.87 ±15.91a 86.40 ±2.89a 73.97 ±1.96a 51.53 ± 2.39a
L 12 373.34 ±8.66a 85.34 ±1.20a 72.63 ±1.14a 49.33 ± 2.44a
H 14 129.01 ±12.81abc 35.26 ±2.23abc 31.46 ±3.13abc 31.25 ±2.20abc
aP<. 01 versus normal control group; bP<. 01 versus model group;
cP<. 01 group treated with low dose of thalidomide versus group treated with high dose of thalidomide.
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Figure 4: Comparison of total Knodell score of liver. N represented
the normal control group; M represented the model group; L rep-
resented the group treated with low dose of thalidomide; H repre-
sented the group treated with high dose of thalidomide. aP<. 01
versus normal control group; bP<. 01 versus model group; cP<. 01
group treated with high dose of thalidomide versus group treated
with low dose of thalidomide.
comparatively severe. And the severity and the distribu-
tion range of hepatocellular necrosis were decreased slightly,
meanwhile the inﬂammatory cell inﬁltration was also de-
creased slightly in this group. Compared with the model
group, the severity of hepatocellularnecrosis and ﬁbroplasias
was signiﬁcantly decreased in the group of rats treated with
high dose of thalidomide, meanwhile there were thin ﬁ-
broseptal and decreased inﬂammatory cell inﬁltration in the
liver, which resulted in the markedly improved or normal ar-
chitecture of hepatic lobule. In general, the histopathology of
liver in the rats treated with high dose of thalidomide resem-
bled relatively that of the normal control. Its total Knodell
score was signiﬁcantly higher than that in the model group
(P<. 01) (Figure 4).
Analysisofserummarkers
Serum ALT and AST were signiﬁcantly higher and PA and
ALB were signiﬁcantly lower in the model group than those
in the normal control group (P<. 01). Serum ALT and AST
were signiﬁcantly lower in group treated with low dose of
thalidomide than those in the model group (P<. 01). Serum
ALT and AST were also signiﬁcantly lower in group treated
with high dose of thalidomide than those in the model group
(P<. 01), meanwhile PA and ALB were signiﬁcantly higher
in this group than those in the model group (P<. 01)
(Table 1).
Serum HA, LN, PCIII, and C IV were signiﬁcantly higher
in the model group than those in the normal control group
(P<. 01).Theyweresigniﬁcantlyloweringrouptreatedwith
high dose of thalidomide than those in the model group (P<
.01) (Table 2).
Immunohistochemicalanalysisof
ICAM-1,VCAM-1,andE-selectin
There were few positive expressions of these three proteins
in the hepatic sinusoid cells and vascular endothelial cells in
the normal rat liver, and there was no positive expression in
the hepatocytes. But in the cirrhotic liver, there were posi-
tive expressions of these three proteins in above three types6 Mediators of Inﬂammation
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Figure 5: Immunohistochemical staining for ICAM-1 in rat liver.
N represented the normal control group; M represented the model
group; L represented the group treated with low dose of thalido-
mide; H represented the group treated with high dose of thalido-
mide. (a) Positive ICAM-1 cells were mainly distributed at the ﬁ-
brosepta band, area of necrosis, and inﬂammatory cell inﬁltration
inhepaticlobules(M,L,andH)(originalmagniﬁcationN,M,L,H,
×400, immunohistochemical staining). (b) Comparison of the ex-
pression of ICAM-1 using immunohistochemical analysis. aP<. 01
versus normal control group; bP<. 01 versus model group; cP<. 01
group treated with high dose of thalidomide versus group treated
with low dose of thalidomide.
of cells, meanwhile the positive ICAM-1, VCAM-1, and E-
selectin cells were mainly distributed at the ﬁbrosepta band,
theareaofnecrosisandinﬂammatorycellinﬁltrationinhep-
atic lobules (Figures 5(a), 6(a), 7(a)). The ratio of these three
positive cells to the total cells in model group was signiﬁ-
cantlyhigherthanthatinthenormalcontrolgroup(P<. 01)
(Figures5(b),6(b),7(b)).Comparedwithmodelgroup,both
lowdoseandhighdoseofthalidomidereducedthatratiosig-
niﬁcantly (P<. 01) (Figures 5(b), 6(b), 7(b)). And there was
signiﬁcant diﬀerence of this eﬀect between these two thera-
peutic groups (P<. 01) (Figures 5(b), 6(b), 7(b)).
WesternblotanalysisofTNF-αprotein
The expression of TNF-α protein was signiﬁcantly higher in
the liver tissue of the rats in the model group than that in the
normal control group (P<. 01) (Figure 8). The expressions
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Figure 6: Immunohistochemical staining for VCAM-1 in rat liver.
N represented the normal control group; M represented the model
group; L represented the group treated with low dose of thalido-
mide; H represented the group treated with high dose of thalido-
mide. (a) Positive VCAM-1 cells were mainly distributed at the ﬁ-
broseptaband,areaofnecrosis,andinﬂammatorycellinﬁltrationin
hepatic lobules (M, L, and H) (original magniﬁcation N, M, L, H,
×400, immunohistochemical staining). (b) Comparison of the ex-
pression of VCAM-1 using immunohistochemical analysis. aP<. 01
versus normal control group; bP<. 01 versus model group; cP<. 01
group treated with high dose of thalidomide versus group treated
with low dose of thalidomide.
ofTNF-αproteinweresigniﬁcantlylowerinthelivertissueof
rats in the group treated with high dose of thalidomide than
that in the model group (P<. 01) (Figure 8).
RT-PCRanalysisofTNF-α,ICAM-1,V CAM-1,
andE-selectinmRNA
The expression of TNF-α mRNA was signiﬁcantly higher in
the liver tissue of the rats in the model group than that in the
normal control group (P<. 01). The expression of TNF-α
mRNA was signiﬁcantly lower in the liver tissue of the rats in
the group treated with high dose of thalidomide than that in
the model group (P<. 01) (Figure 9).
The expressions of ICAM-1, VCAM-1, and E-selectin
mRNA were signiﬁcantly higher in the liver tissue of the
rats in the model group than those in the normal control
group (P<. 01). The expressions of ICAM-1, VCAM-1, andPeng Lv et al 7
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Figure 7: Immunohistochemical staining for E-selectin in rat liver.
N represented the normal control group; M represented the model
group; L represented the group treated with low dose of thalido-
mide; H represented the group treated with high dose of thalido-
mide. (a) Positive E-selectin cells were mainly distributed at the
ﬁbrosepta band, area of necrosis, and inﬂammatory cell inﬁltra-
tion in hepatic lobules (M, L, and H) (original magniﬁcation N,
M, L, H, ×400, immunohistochemical staining). (b) Comparison
of the expression of E-selectin using immunohistochemical analy-
sis. aP<. 01 versus normal control group; bP<. 01 versus model
group; cP<. 01 group treated with high dose of thalidomide versus
group treated with low dose of thalidomide.
E-selectin mRNA were signiﬁcantly lower in the liver tissue
of the rats in the group treated with low dose of thalidomide
or high dose of thalidomide than that in the model group,
respectively, (P<. 01) (Figure 9). And there was signiﬁcant
diﬀerence of this eﬀect between these two therapeutic groups
(P<. 01) (Figure 9).
Analysisofcorrelation
There was a close positive correlation between the expres-
sion of TNF-α mRNA and that of ICAM-1 mRNA (r = .83,
P<. 01), VCAM-1 mRNA (r = .92, P<. 01), and E-selectin
mRNA (r = .94, P<. 01).
DISCUSSION
Liverﬁbrosisisacommonpathologicprocessofchronicliver
diseasesofvariousetiologies.Thechronicliverdiseaseofvar-
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Figure 8: Expression of TNF-α protein in rat liver using Western
blot analysis. (a) Lane 1 represented the normal control group (N);
lane 2 represented the model group (M); lane 3 represented the
group treated with low dose of thalidomide (L); lane 4 represented
the group treated with high dose of thalidomide (H). β-actin served
as an internal control. (b) Comparison of the expression of TNF-
α protein using Western blot analysis. aP<. 01, bP<. 05 versus
normal control group; cP<. 01 versus model group; dP<. 01 group
treated with high dose of thalidomide versus group treated with low
dose of thalidomide.
ious etiologies produces liver ﬁbrosis and progressive contin-
ual of ﬁbrosis will end up ﬁnally into the cirrhosis [19, 20].
It has been reported that liver ﬁbrosis may be reversed by
so many treatments, which included antiviral therapy, reg-
ulation of matrix metabolism, facilitation of apoptosis of
hepatocellular satellate cell (HSC), gene therapy, and so on
[21, 22].
In recent years, thalidomide has been used in some ba-
sic and clinical trials to treat acute or chronic liver dis-
eases [23–29]. Muriel et al reported that thalidomide sig-
niﬁcantly reduced the increase of ALT, γ-GTP, and ALP,
prevented the lipid peroxidation and the decrease of glyco-
gen, and improved the histopathology in rat liver cirrho-
sis induced by CCl4 [30]. Its mechanism may be related to
anti-inﬂammatory, anti-TNF-α, and antiﬁbrotic properties
of thalidomide. In another study, Yeh et al reported that in-
traperitoneal injection of thalidomide inhibit lethal hepatic
necroinﬂammation,acceleratedtherecoveryfromtheratlive
cirrhosis induced by thioacetamide, and the mechanism may
be suppression of expression of TNF-α and TGFβ1o fK u p f -
fer’s cells [31].8 Mediators of Inﬂammation
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Figure 9: Expression of TNF-α, ICAM-1, VCAM-1, and E-selectin mRNA in rat liver using RT-PCR analysis. (a) Lane 1 represented 100bp
maker, lane 2 represented the normal control group (N); lane 3 represented the model group (M); lane 4 represented the group treated with
low dose of thalidomide (L); lane 5 represented the group treated with high dose of thalidomide (H). GAPDH served as an internal control.
(b) Comparison of the expression of TNF-α, ICAM-1, VCAM-1, and E-selectin mRNA using RT-PCR analysis. aP<. 01 versus normal
control group; bP<. 01 versus model group; cP<. 01 group treated with high dose of thalidomide versus group treated with low dose of
thalidomide.
In our study, the rat liver cirrhosis induced by CCl4 was
treated with thalidomide by intragastric administration. The
mortality of rats was decreased and their healthy status was
improved. And the appearance of the liver after the therapy
with high dose of thalidomide became smooth and supple.
The histopathology of liver tissue of rats treated with high
dose of thalidomide appeared approximate to the normal
liver. The decrease of hepatocellular necrosis, inﬂammatory
inﬁltration, and ﬁbroplasias and the absorption of ﬁbrosepta
were apparent in liver. The signiﬁcant decrease of Knodell
scoredemonstratedthattheactivityofinﬂammationandde-
gree of ﬁbrosis were markedly reduced by thalidomide (high
dose). Besides this, thalidomide (low dose and high dose)
prevented the evaluation of serum ALT and AST, which sug-
gests that it can eﬀectively prevent the inﬂammation. The in-
creased levels of PA and ALB in the thalidomide (high dose)
treated group suggests that thalidomide can improve the nu-
tritional status of cirrhotic rats. The reduced serum liver ﬁ-
brosis makers such as HA, LN, PCIII, and C IV in rat cirrho-
sis indicated thalidomide’s (high dose) eﬀect on improving
of liver ﬁbrosis on another hand.
The expression of adhesion molecules such as ICAM-1,
VCAM-1, and E-selectin was high in the chronic hepatitis, or
cirrhosis was reported in several studies, and these adhesion
molecules may play roles in the pathogenesis of liver ﬁbro-
sis. In our study very less expression of these molecules was
foundinthenormalliver,butinthecirrhoticliver,therewere
high expressions of them in the hepatic sinusoid cells, vascu-
lar endothelial cells, and hepatocytes. They were distributed
at the ﬁbrosepta band, area rich of necrosis, and inﬂamma-
tory cells in cirrhotic liver. It was found that the expres-
sions of ICAM-1, VCAM-1, and E-selectin both in mRNA
and protein levels were signiﬁcantly reduced by thalidomide
which was dose dependent. This suggests that thalidomide
can much eﬀectively suppress the up-regulation of adhesion
molecules in liver cirrhosis. This may be useful to illustrate
the mechanism of thalidomide’s eﬀect on preventing liver ﬁ-
brosis.
TNF-α/TNFR-mediated signaling pathway via activation
of Kupﬀer’s cells plays an important role in the pathogene-
sis of liver ﬁbrosis [32]. Sudo et al reported that liver ﬁbro-
sis induced by CCl4 was prevented in TNF receptor (TNFR)
type 1 knockout (KO) mice [33]. But as an important proin-
ﬂammatory cytokine, TNF-α also plays an important role
in the regulation of adhesion molecules [34–40]. Enhance-
ment of NFκB mediated signaling pathway via activation by
cytokines like TNF-α may be critically involved in the up-
regulation of chemokines and adhesion molecules [41–43].
Paik et al reported that HSC may be activated by produc-
tion of TNF-α induced by LPS, and activated HSCs stimulate
NFκBwhichup-regulatesadhesionmoleculessuchasICAM-
1 and VCAM-1 [44]. It is a proinﬂammatory mediator cas-
cade which plays important role in the pathogenesis of liver
ﬁbrosis. A promising therapeutic approach to liver ﬁbrosis
is, therefore, to inhibit TNF-α-induced adhesion molecules
expression at the transcription level. Thalidomide has been
shown to reduce the production of TNF-α eﬀectively [45–
47]. In this study, the expression of TNF-α in mRNA and
protein levels were markedly reduced by thalidomide (high
dose) in liver cirrhosis induced by CCl4. And there was a
close positive correlation between the expression of TNF-
α mRNA and that of ICAM-1 mRNA (r = .83, P<. 01),Peng Lv et al 9
VCAM-1 mRNA (r = .92, P<. 01), and E-selectin mRNA
(r = .94, P<. 01), which manifested that the changes of
adhesion molecules were closely correlated with TNF-α in
mRNA levels induced by thalidomide in rat liver cirrhosis.
So maybe suppression of adhesion molecules via TNF-α sig-
naling pathway by thalidomide plays an essential role in the
treatment of liver ﬁbrosis. Even though there were 10-fold
diﬀerence between high dose and low dose of thalidomide,
both of them signiﬁcantly reduced the expression of ICAM-
1, VCAM-1, and E-selectin in mRNA and protein levels. It is
so interesting. Maybe either there were other proinﬂamma-
tory cytokines suppressed by thalidomide that also mediated
the expression of adhesion molecules or there were some sig-
naling pathways unknown which played roles in this regula-
tion.
In conclusion, thalidomide exerts its eﬀect on the down-
regulation of adhesion molecules via TNF-α signaling path-
way to prevent liver injury and inhibit the developing of liver
ﬁbrosis.
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